ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team ITFG/IPAC TECHNICAL TEAM: SUPPLIER QUALITY CONTROL (QUALIFICATION) Presented by: Gordon.

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

When is Excipient Reduced Testing Appropriate?
Roadmap for Sourcing Decision Review Board (DRB)
Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
Company Confidential Registration Management Committee (RMC) Other Party (OP) Assessor Workshop San Diego, CA January 20, AS9104/2 Oversight Process.
First Evaluation of Good Governance for Medicines Programme Brief Summary of Findings.
Intentional Adulteration Phase 2 Workgroup 1.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
© 2011 Underwriters Laboratories Inc. Product Recall and the Supply Chain: ISO Best Practices Robert Pollock Chair, US Technical Advisory Group for ISO.
Understanding CGMPs – What Attorneys Need to Know The Nuts & Bolts of CGMPs: FDA Guidance for Industry Paula R. Katz Acting Branch Chief, Regulatory Policy.
Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.
Presentation By: Chris Wade, P Eng. Finally … a best practice for selecting an engineering firm.
1 Purchasing and Procurement Processes Module Four Revision Date: 2/06/2015.
Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.
FPSC Safety, LLC ISO AUDIT.
Regulatory requirements and benefits converting to Continued Process Verification.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Creating a world where environmental sustainability and social justice are the normal conditions of business
WHAT IS ISO 9000 ? Founded in 1946 in Geneva, Switzerland. ISO 9000 is an internationally recognised quality management system developed by ISO (International.
SE513 Software Quality Assurance Lecture04: Contract Review Galin, SQA from Theory to Education Limited 2004.
Selection Sourcing Structure Standardization Safety Substantiation
Ashland Specialty Ingredients IFAC’s cGMP Audit Guide How the Food Ingredient Industry has Responded to FSMA and Food Safety Audits Priscilla Zawislak.
SupplySide East, April 28, 2009Council for Responsible Nutrition Ingredient Supplier Qualification Implementation of the SIDI™ protocol.
ITFG/IPAC Collaboration OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.
GS1 US INITIATIVES UPDATE MARCH 18, GS1 STANDARDS MAKES IT POSSIBLE 2 SAFETYSECURITY VISIBILITYEFFICIENCY COLLABORATION To apply standards to business.
Copyright © 2009 NDIA PMSC Robert Loop August 2009 NDIA PMSC Guides Working Group Status.
ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville,
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
2012 Joint Guideline Launch GUIDELINE FOR RAW MATERIALS GOOD SUPPLIER PRACTICE.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Ann Van Meter Business Quality Leader – Dow Pharma & Food Solutions
PRODUCT TRANSFER.
EXCiPACT TM EXCiPACT TM International Pharmaceutical Excipients Certification Minimize risks – maximize benefits.
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
Supply Chain Risk Leadership Council 1 SCRLC August Supply Chain Risk Leadership Council August 2009 Meeting.
Important informations
Total Excipient Control (TEC) Tools for Managing Excipient Quality A Pathway to Increased Patient Safety David R. Schoneker Vice Chair – Maker and Distributor.
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products: Work of the ITFG/IPAC-RS Collaboration Presented by Cynthia.
© 2007 Pearson Education Managing Quality Integrating the Supply Chain S. Thomas Foster Chapter 16 Implementing and Validating the Quality System.
SIDI™ ppt V Standardized Information on Dietary Ingredients (SIDI™) A joint trade association initiative to standardize ingredient information.
Presented by CIDA on behalf of the Task Team on Multilateral Effectiveness.
Solicitation and Selection Guidance April 27,2015.
Supply Chain Risk Leadership Council 1 SCRLC May 2009.
Overview of FDA's Regulatory Framework for PET Drugs
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
WEC MADRID 18 TH MARCH 2004 ASTRAZENECA’S APPROACH TO SUPPLIER RISK MANAGEMENT.
Molecule-to-Market-Place Quality
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
Gulay Litchfield For CQI-TECH PLC
ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.
Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.
IPEC Overview The Impact of Globalisation and IPEC’s Role Janeen Skutnik Past Chair – IPEC Americas.
ITFG/IPAC Collaboration BA/BE Technical Team ITFG/IPAC TECHNICAL TEAM: BA/BE IN VITRO AND IN VIVO TESTS Presented by: Stephen Farr, PhD 26 April 2000 Rockville,
Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.
Fédération Internationale des Ingénieurs-Conseils BIMILACI 2007 FIDIC Tools and Initiatives on Integrity Management Washington, May 11, 2007 Dr. Jorge.
1 “Good Practices in Managing for Results” Workshop Santiago, Chile October 27 th and 28 th, 2010 Benjamin Nelson Managing Director for Quality Office.
ITFG/IPAC Collaboration CMC Leachables and Extractables Technical Team ITFG/IPAC TECHNICAL TEAM: CMC LEACHABLES AND EXTRACTABLES Presented by: Kaushik.
Product & Process Working Group February 26, 2002.
Update of API Standards for Supply Chain Management API Standard 20J – Qualification of Distributors.
Software Quality Assurance
Pharmaceutical Quality Control & current Good Manufacturing Practice
Pre-Investigational New Drug (pre-IND) Meeting with FDA
Some Information about Supply Chain Management Stages
Bio-Facility Qualification, Start-Up & Licensure
The role of the ECCP (1) The involvement of all relevant stakeholders – public authorities, economic and social partners and civil society bodies – at.
Guideline for Elemental Impurities ICH Q3D(R)
Presentation transcript:

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team ITFG/IPAC TECHNICAL TEAM: SUPPLIER QUALITY CONTROL (QUALIFICATION) Presented by: Gordon Hansen 26 April 2000 Rockville, MD

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team SUPPLIER QUALITY CONTROL TEAM Team membership is comprised of representatives from 9 pharma companies and 5 key component manufacturers.

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team SUPPLIER QUALITY CONTROL TEAM A core theme of the draft CMC guidances with respect to component, excipient, and raw material suppliers is summarized below: Tight standards and extensive testing by the pharma manufacturer are required in order to assure batch to batch quality of components and excipients.

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team TEAM’S THESIS The qualification and control of critical components (in the areas of performance related physical testing, extractables and leachables) and excipients should be achieved by a combination of appropriate scientific practices, cGMP controls and supplier qualification systems.

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team TEAM’S APPROACH: cGMP SURVEY A survey of suppliers was conducted to evaluate quality and compliance practices at all stages of component, excipient, raw materials, and active drug substance manufacture Survey requested assessment of performance related to 31 specific cGMP elements Circulated to all companies represented on Team Information obtained on 53 suppliers, from raw materials through finished component manufacture

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team TEAM’S APPROACH: cGMP SURVEY Results: Highest level of compliance is evident with active ingredient suppliers Level of cGMP awareness and compliance in the component and raw material supply chain is increasing, but needs to be improved Specific cGMP program elements remain to be generally accepted and implemented, especially early in supply chain

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team TEAM’S APPROACH: cGMP SURVEY Results: No generally accepted cGMP guidelines exist for the component supply chain cGMP guidelines have been drafted by IPEC (International Pharmaceutical Excipients Council)

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team PROPOSALS AND COMMITMENTS The Team endorses the IPEC Guideline for the control and cGMP compliance of excipients The Team proposes that an industry-wide initiative be established to develop a cGMP guideline for component suppliers

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team PROPOSALS AND COMMITMENTS The Team requests that the Agency partner with the pharma industry and component suppliers by: Formally recognizing the value of a cGMP guideline for component suppliers by acknowledging in the guidance documents that if sufficient supplier control mechanisms are in place, appropriate reductions in testing will be considered. Establishing key elements and expectations for a cGMP guideline. Participation in reviewing and commenting on draft cGMP guidelines.